东部地区慢性乙型肝炎患者口服抗病毒药物治疗的临床特征

StephenW

Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China

    Jueqing Gu, Guodong Yu, Xiaoli Zhang, Shanyan Zhang, Huan Cai, Chanyuan Ye, Yida Yang, Dezhou Li, Zhaowei Tong, Huajiang Shen, Huazhong Chen, Feng Ding, Xijie Lai, Junyan Liu, Meiling Xu & Weiti Wu

Virology Journal volume 18, Article number: 19 (2021) Cite this article

    Metrics details

Abstract
Background

In China, more than 20 million patients with chronic hepatitis B need antiviral treatment. Side effects of antiviral treatment such as renal complications can be problematic, particularly in an aging population.
Methods

The data were retrospectively extracted from the hospital medical charts of five centers in eastern China from January 1 to December 31, 2018.
Results

A total of 8309 patients with CHB was enrolled in this study. The median age of the patients was 46 years. The prevalence of diabetes mellitus, hypertension, and hepatic cirrhosis was respectively 3.49%, 4.42%, and 23.72%. The prevalence of these comorbidities increased with age (P < 0.001). Of the patients with CHB, 5332 had complete renal function results. Among them, patients with an estimated glomerular filtration rate of < 60 mL/min/1.73m2 accounted for 4.14%, and those with proteinuria for 8.33%. According to the definition of chronic kidney disease, the proportion of patients with chronic kidney disease was 11.37%. The prevalence of chronic kidney disease increased with age (P < 0.001). In a multivariate analysis, age group [odds ratio (OR) = 2.387], diabetes mellitus (OR = 1.486), hypertension (OR = 2.557), hepatic cirrhosis (OR = 1.295), and a history of exposure to adefovir dipivoxil (OR = 1.644) were significantly associated with CKD (P < 0.05). Among patients with CKD, 17.66% (107/606) had a history of lamivudine exposure, and 34.65% (210/606) had a history of nucleotide analogue exposure
Conclusion

The management of Chinese patients with CHB should take into consideration age, previous medication history, and renal impairment.

StephenW

东部地区慢性乙型肝炎患者口服抗病毒药物治疗的临床特征横断面回顾性分析

    顾觉清，余国栋，张晓丽，张珊艳，蔡欢，叶禅媛，杨怡达，李德洲，童兆伟，沉华江，陈华忠，丁枫，赖锡杰，刘俊彦，徐美玲，吴维iti

病毒学杂志第18卷，文章编号：19（2021）引用本文

    指标详细信息

抽象
背景

在中国，超过2000万的慢性乙型肝炎患者需要抗病毒治疗。抗病毒治疗的副作用（例如肾脏并发症）可能会成问题，特别是在老龄化人群中。
方法

数据回顾自2018年1月1日至12月31日中国东部五个中心的医院病历表。
结果

本研究共纳入8309名CHB患者。患者的中位年龄为46岁。糖尿病，高血压和肝硬化的患病率分别为3.49％，4.42％和23.72％。这些合并症的患病率随着年龄的增长而增加（P <0.001）。在CHB患者中，有5332个具有完整的肾功能结果。其中，肾小球滤过率估计≤60mL / min / 1.73m2的患者占4.14％，蛋白尿的患者占8.33％。根据慢性肾脏病的定义，慢性肾脏病患者的比例为11.37％。慢性肾脏病的患病率随年龄增长而增加（P <0.001）。在多变量分析中，年龄组[比值比（OR）== 2.387]，糖尿病（OR = 1.486），高血压（OR = 2.557），肝硬化（OR = 1.295）和接触阿德福韦酯的历史（OR = 1.644）与CKD显着相关（P <0.05）。在CKD患者中，有17.6％（107/606）有拉米夫定暴露史，有34.65％（210/606）有核苷酸类似物暴露史。
结论

中国CHB患者的治疗应考虑年龄，既往用药史和肾功能不全。

StephenW

https://virologyj.biomedcentral. ... /s12985-021-01491-6

乙肝人1949

感觉未有用